Little Green Pharma Ltd
LGP.ASXHealth Care
Market Data
$0.087
+0.0%$26.7M
-100000.0x
$-0.005
0.00%
-0.2%
Latest Earnings
Appendix 4E and 2026 Annual Report
21 May 2026
Little Green Pharma delivered strong FY2026 results with record revenue of $42.5M (+15.3% YoY) and Adjusted EBITDA of $6.5M (up 124% from $2.9M), though net profit swung to a loss of $1.4M from prior year profit of $3.3M due to inventory write-downs and share-based payments. Europe emerged as the primary growth driver, with German and UK markets performing strongly, while the company maintains a solid balance sheet with net tangible assets of 23.29 cents per share. Key points: Record revenue of $42.5M, up 15.3% YoY driven by strong international market growth; Adjusted EBITDA increased significantly to $6.5M from $2.9M (124% growth), demonstrating operational leverage; Europe emerged as primary growth driver, with European revenue exceeding Australian revenue in Q4; Germany and UK showing strong demand
Recent Announcements
Appendix 4E and 2026 Annual Report
Little Green Pharma delivered strong FY2026 results with record revenue of $42.5M (+15.3% YoY) and Adjusted EBITDA of $6.5M (up 124% from $2.9M), though net profit swung to a loss of $1.4M from prior year profit of $3.3M due to inventory write-downs and share-based payments. Europe emerged as the primary growth driver, with German and UK markets performing strongly, while the company maintains a solid balance sheet with net tangible assets of 23.29 cents per share. Key points: Record revenue of $42.5M, up 15.3% YoY driven by strong international market growth; Adjusted EBITDA increased significantly to $6.5M from $2.9M (124% growth), demonstrating operational leverage; Europe emerged as primary growth driver, with European revenue exceeding Australian revenue in Q4; Germany and UK showing strong demand
Get real-time alerts for LGP
Receive AI-powered earnings summaries and instant notifications when Little Green Pharma Ltd releases results.
Register Free